Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), taking place 11 to 13 October 2023.

Real-world and clinical data will provide further evidence to support the established safety and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in treating anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), furthering the Company's ambition to redefine care for people living with this disease.

Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: "Our data at MSMilan2023 emphasize the promise of C5 inhibition in NMOSD and offer insights to help guide clinical decision-making and care. Alexion remains committed to advancing understanding of this rare neurological disease, the patient experience and the role of our medicines in helping to prevent debilitating relapses."

Reinforcing the potential of C5 inhibition to transform treatment landscape for AQP4 Ab+ NMOSD
A late-breaking poster presentation will detail encouraging safety findings for patients with AQP4 Ab+ NMOSD who switched from rituximab to C5 inhibitor therapy in the Phase III CHAMPION-NMOSD and PREVENT clinical trials. This post-hoc analysis will show no differences in safety outcomes among patients who used rituximab three to twelve months prior to their first dose of Ultomiris or Soliris and provide information to guide clinical decision-making when considering a switch from rituximab to C5 inhibitor therapy.

Additionally, three-year post-marketing surveillance data of Soliris among Japanese patients has been shortlisted to be qualified for one of the Five Best Poster Awards at the Congress. Findings will illustrate that the real-world safety and efficacy of Soliris in Japanese patients with AQP4 Ab+ NMOSD are consistent with results from the Phase III PREVENT trial. The results will also show that concomitant immunosuppressive therapy (IST) use decreased over time among patients treated with Soliris, reinforcing the potential of Soliris to reduce IST burden for patients.

Further, a poster presentation will outline long-term safety data in Ultomiris­- and Soliris-treated patients from clinical trials and post-marketing surveillance across indications, with a focus on meningococcal infection data. Results will show meningococcal infection rates and infection-related mortality rates remained stable, even as the number of patients treated with Soliris increased over time. In addition, results will indicate comparable rates among Ultomiris-treated patients.
Alexion presentations during MSMilan2023

Lead Abstract Title  Presentation Details 
Author 
 
Levy, Safety findings in patients with AQP4+ Poster Presentation P378 
Michael NMOSD who received eculizumab or 11 October 2023 
ravulizumab in the PREVENT and CHAMPION 16:30-18:30 CEST 
-NMOSD studies and had received  
rituximab within 1 year prior to
enrolment 
Nakahara, Long-term safety and effectiveness of Poster Presentation P010 
Jin eculizumab in patients with AQP4+ 11 October 2023 
neuromyelitis optica spectrum disorder: 16:30-18:30 CEST 
3 years of data from Japanese post  
-marketing surveillance 
Lee, Switching from rituximab to eculizumab Poster Presentation P358 
Justin in patients with AQP4+ NMOSD in the 11 October 2023 
United States: Impact on 16:30-18:30 CEST 
hospitalisations and comorbidities   
Fam, Sami Meningococcal infections in eculizumab- Poster Presentation P410 
or ravulizumab- treated patients with 12 October 2023 
neuromyelitis optica spectrum disorder: 17:00-19:00 CEST 
a clinical and real-world  
pharmacovigilance update across
indications 
Papp, The socio-economic burden of AQP4 Poster Presentation P490 
Viktoria -antibody seropositive NMOSD: a 12 October 2023 
national-wide registry-based study*  17:00-19:00 CEST 
 
Vives, NMOSDCopilot, a software as a medical Poster Presentation P1034 
Alize device for patients with NMOSD: a ePoster only
patient-centred usability study**   
Francis, Excess mortality, causes of death and Poster Presentation P1018 
Anna last EDSS score prior to death in ePoster only
patients with AQP4 antibody positive  
neuromyelitis optica spectrum disorder 

*Odense University Hospital study supported by Alexion

**Ad Scientiam research study supported by Alexion

Notes

Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on social media @AstraZeneca (https://www.linkedin.com/company/astrazeneca/mycompany/verification/).

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).